Retatrutide vs Semaglutide: What the Math Predicts

If you line up the headline numbers — roughly 24% body weight loss for retatrutide versus 15% for semaglutide — it looks like a clear winner. But those figures come from different trials, different timelines, and different populations. Before treating the math as settled, it's worth understanding why retatrutide appears to outperform, and where the comparison gets genuinely murky.

What retatrutide actually targets

Semaglutide is a GLP-1 receptor agonist — it mimics the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and improve insulin response. That single-receptor strategy is what powered the STEP trials and Wegovy's FDA approval.

Retatrutide is a triple agonist: it hits GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously.

• GLP-1 activation does the same work it does in semaglutide — appetite suppression, slower digestion
• GIP activation amplifies insulin release and appears to enhance the weight-loss effect of GLP-1 (tirzepatide already exploits this pairing)
• Glucagon receptor activation is the new lever — glucagon promotes fat breakdown and raises resting energy expenditure

The glucagon piece is what separates retatrutide from tirzepatide. Adding glucagon receptor activity theoretically burns more fat even at rest, layering an energy-expenditure effect on top of the appetite suppression both drugs share.

The trial numbers, in context

Retatrutide (phase 2, Jastreboff et al., NEJM 2023):

The 24% figure cited in many summaries refers to a 24-mg exploratory group; the phase 3 program is testing 8 mg and 12 mg doses. The trial enrolled adults with obesity (BMI ≥ 30) and no type 2 diabetes, ran 48 weeks, and had 338 participants.

Semaglutide (STEP-1, Wilding et al., NEJM 2021):

STEP-1 enrolled 1,961 adults with obesity or overweight with a weight-related comorbidity, ran 68 weeks, and used the approved Wegovy dose.

The honest comparison caveat: Retatrutide's 22.8% came at 48 weeks; semaglutide's 14.9% came at 68 weeks. GLP-1-class drugs continue to produce weight loss beyond week 48 in long-term follow-up. What retatrutide's weight loss curve looks like at 68 or 72 weeks won't be known until phase 3 data matures.

Where tirzepatide fits in

For those already familiar with tirzepatide (Mounjaro/Zepbound), the logical question is: does retatrutide meaningfully outperform a dual agonist?

In SURMOUNT-1, tirzepatide at 15 mg produced 22.5% mean weight loss at 72 weeks. Retatrutide's phase 2 12-mg group hit 22.8% at 48 weeks — a slightly higher number at a shorter duration. The glucagon receptor addition does appear to shift results upward, though by how much, in a head-to-head trial, is still unknown. No retatrutide-vs-tirzepatide comparison exists.

The honest answer: retatrutide appears to narrow the remaining gap between GLP-1 drugs and bariatric surgery weight loss (which averages 25–30% for sleeve gastrectomy). Whether it crosses that threshold in phase 3, and whether that advantage holds up for the majority of patients rather than the high-response tail, is the open question.

Side effect profile: an extra lever means extra risks

More receptor targets means a more complex side effect picture.

GLP-1 and GIP side effects — nausea, vomiting, diarrhea, constipation — are expected with retatrutide and were observed in the phase 2 trial. At higher doses, heart rate increases were notably larger than typically seen with semaglutide. In the 12-mg retatrutide group, mean heart rate increased by about 5–6 bpm over baseline; semaglutide raises heart rate by roughly 1–2 bpm on average.

The glucagon activation also raises a theoretical concern about lean mass loss. Glucagon is catabolic — it promotes glucose release from muscle and liver. Whether that translates to greater muscle loss than tirzepatide or semaglutide will require detailed body composition data from phase 3.

What "not yet FDA-approved" means practically

As of 2026, retatrutide is in phase 3 trials. It has no approved indication, no approved brand name, and no approved dosing protocol. The comparison to semaglutide is, right now, a comparison of trial data to trial data, not approved drug to approved drug.

That matters for a few reasons:

• Phase 3 trials often produce more modest results than phase 2, as participant populations broaden and doses are refined
• Long-term safety data does not yet exist at scale
• Insurance coverage, access, and cost are all unknowns

If you're on semaglutide (Ozempic or Wegovy) today and the phase 3 results confirm the phase 2 signal, switching would be a clinical decision made in partnership with your prescriber — not a math exercise you can run from trial abstracts.

The mechanism-gap summary

Each additional receptor appears to add roughly 7–8 percentage points of weight loss in trial conditions. Whether that pattern holds at population scale — and whether patients tolerate triple agonism as well as dual or single agonism — is what phase 3 data will answer.

The math predicts a gap. The mechanism explains why. What it can't tell you yet is whether retatrutide's side effect trade-offs, long-term cardiovascular profile, and real-world response distribution justify the headline number.

Related reading

• Semaglutide guide — how Wegovy and Ozempic work, dosing, and what to expect
• Tirzepatide vs semaglutide — the dual-agonist comparison
• SURMOUNT trial results — tirzepatide's phase 3 data in detail
• Weight loss timelines by month — what realistic progress looks like on GLP-1s